aTyr Pharma, Inc. ATYR

ATYR Company Overview

aTyr Pharma, Inc. is a U.S.-based biotechnology company focused on developing therapeutics derived from extracellular functions of transfer RNA synthetase biology. The company operates within the biopharmaceutical and immunology sectors, with a primary emphasis on inflammatory lung diseases and immune-mediated disorders. Its lead product candidate is efzofitimod, an investigational biologic designed to modulate immune responses through interaction with neuropilin-2 pathways. The company’s research platform is centered on novel physiological activities associated with tRNA synthetases, which historically were known primarily for their role in protein synthesis.

The company generates value primarily through clinical-stage drug development, strategic research collaborations, and intellectual property associated with its discovery platform. aTyr Pharma has positioned itself within the rare and orphan disease market, particularly in pulmonary inflammation and interstitial lung disease indications. Founded in 2005, the company emerged from discoveries made at The Scripps Research Institute regarding noncanonical functions of aminoacyl-tRNA synthetases. Over time, the company shifted from broader platform exploration toward a more focused clinical strategy centered on immunology and pulmonary medicine.